newsfilter
← Latest News
GlobeNewswire·

NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference

PITTSBURGH and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of